Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial
Author:
Ferreri Andrés J. M.ORCID, Cwynarski KateORCID, Pulczynski Elisa, Fox Christopher P., Schorb Elisabeth, Celico Claudia, Falautano Monica, Nonis Alessandro, La Rosée PaulORCID, Binder Mascia, Fabbri Alberto, Ilariucci Fiorella, Krampera MauroORCID, Roth Alexander, Hemmaway Claire, Johnson Peter W., Linton Kim M., Pukrop Tobias, Gørløv Jettes Sønderskov, Balzarotti Monica, Hess GeorgORCID, Keller UlrichORCID, Stilgenbauer Stephan, Panse JenseORCID, Tucci AlessandraORCID, Orsucci Lorella, Pisani Francesco, Zanni Manuela, Krause Stefan W.ORCID, Schmoll Hans J., Hertenstein Bernd, Rummel Mathias, Smith Jeffery, Thurner Lorenz, Cabras Giuseppina, Pennese Elsa, Ponzoni Maurilio, Deckert Martina, Politi Letterio S., Finke JurgenORCID, Ferranti Antonella, Cozens Kelly, Burger Elvira, Ielmini Nicoletta, Cavalli Franco, Zucca EmanueleORCID, Illerhaus Gerald,
Funder
Ministry of Health, Italy | Agenzia Italiana del Farmaco, Ministero della Salute Cancer Research UK Oncosuisse Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Cancer Research,Hematology
Reference24 articles.
1. Ferreri AJ, Cwynarski K, Pulczynski E, Ponzoni M, Deckert M, Politi LS, et al. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematol. 2016;3:e217–27. 2. Ferreri AJM, Cwynarski K, Pulczynski E, Fox CP, Schorb E, La Rosee P, et al. Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. Lancet Haematol. 2017;4:e510–23. 3. Scordo M, Wang TP, Ahn KW, Chen Y, Ahmed S, Awan FT, et al. Outcomes associated with thiotepa-based conditioning in patients with primary central nervous system lymphoma after autologous hematopoietic cell transplant. JAMA Oncol. 2021;7:993–1003. 4. Ferreri AJ, Illerhaus G. The role of autologous stem cell transplantation in primary central nervous system lymphoma. Blood. 2016;127:1642–9. 5. Illerhaus G, Kasenda B, Ihorst G, Egerer G, Lamprecht M, Keller U, et al. High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial. Lancet Haematol. 2016;3:e388–97.
Cited by
77 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|